110 related articles for article (PubMed ID: 26998706)
1. Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Investig Drugs; 2016 Jun; 25(6):729-34. PubMed ID: 26998706
[TBL] [Abstract][Full Text] [Related]
2. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC
J Clin Oncol; 2009 Dec; 27(35):6012-8. PubMed ID: 19826119
[TBL] [Abstract][Full Text] [Related]
4. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Chen R; Keating MJ; Gandhi V; Plunkett W
Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Blum KA; Ruppert AS; Woyach JA; Jones JA; Andritsos L; Flynn JM; Rovin B; Villalona-Calero M; Ji J; Phelps M; Johnson AJ; Grever MR; Byrd JC
Leukemia; 2011 Sep; 25(9):1444-51. PubMed ID: 21606960
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.
Stephens DM; Ruppert AS; Blum K; Jones J; Flynn JM; Johnson AJ; Ji J; Phelps MA; Grever MR; Byrd JC
Haematologica; 2012 Mar; 97(3):423-7. PubMed ID: 22271900
[TBL] [Abstract][Full Text] [Related]
7. Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.
Gosangi B; Davids M; Somarouthu B; Alessandrino F; Giardino A; Ramaiya N; Krajewski K
Cancer Imaging; 2018 Apr; 18(1):13. PubMed ID: 29669600
[TBL] [Abstract][Full Text] [Related]
8. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.
Yigit B; Halibozek PJ; Chen SS; O'Keeffe MS; Arnason J; Avigan D; Gattei V; Bhan A; Cen O; Longnecker R; Chiorazzi N; Wang N; Engel P; Terhorst C
Oncotarget; 2016 May; 7(18):26346-60. PubMed ID: 27029059
[TBL] [Abstract][Full Text] [Related]
9. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
10. Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century.
Pulte D; Castro FA; Jansen L; Luttmann S; Holleczek B; Nennecke A; Ressing M; Katalinic A; Brenner H;
J Hematol Oncol; 2016 Mar; 9():28. PubMed ID: 27000264
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol: An Old Drug With New Perspectives? Implication for Development of New Drugs.
Cimini A; d'Angelo M; Benedetti E; D'Angelo B; Laurenti G; Antonosante A; Cristiano L; Di Mambro A; Barbarino M; Castelli V; Cinque B; Cifone MG; Ippoliti R; Pentimalli F; Giordano A
J Cell Physiol; 2017 Feb; 232(2):312-322. PubMed ID: 27171480
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
Awan FT; Jones JA; Maddocks K; Poi M; Grever MR; Johnson A; Byrd JC; Andritsos LA
Ann Hematol; 2016 Jun; 95(7):1137-43. PubMed ID: 27118540
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.
Lamothe B; Wierda WG; Keating MJ; Gandhi V
Clin Cancer Res; 2016 Sep; 22(18):4712-26. PubMed ID: 27026200
[TBL] [Abstract][Full Text] [Related]
14. Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study.
Friedman DR; Sibley AB; Owzar K; Chaffee KG; Slager S; Kay NE; Hanson CA; Ding W; Shanafelt TD; Weinberg JB; Wilcox RA
Am J Hematol; 2016 Jul; 91(7):687-91. PubMed ID: 27037726
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
16. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
[No Abstract] [Full Text] [Related]
17. The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
Seiler T; Hutter G; Dreyling M
Drugs; 2016 Apr; 76(6):639-46. PubMed ID: 27052260
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
19. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
20. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Zoellner AK; Höhler T; Fries S; Böhme A; Kiewe P; Kellermann L; Dreyling M
Ann Hematol; 2016 May; 95(6):853-61. PubMed ID: 27021305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
